Merck's Phase 3 KEYNOTE‑C93 Trial Evaluating KEYTRUDA Met Primary Endpoint Of Progression-Free Survival For Treatment Of Patients With Mismatch Repair Deficient Advanced Or Recurrent Endometrial Cancer
Merck's Phase 3 KEYNOTE‑C93 Trial Evaluating KEYTRUDA Met Primary Endpoint Of Progression-Free Survival For Treatment Of Patients With Mismatch Repair Deficient Advanced Or Recurrent Endometrial Cancer
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day